Get the latest news, insights, and market updates on RYTM (Rhythm Pharmaceuticals, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones
-- Q4 2025 preliminary net product revenues from global sales of IMCIVREE® (setmelanotide) of approximately $57 million for the fourth quarter of 2025, an 11% increase over Q3 2025 -- -- FY 2025 preliminary net product revenue of approximately $194 million, approximately 50% increase from FY2024 -- -- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity -- -- On track to report topline data from 12-patient Japanese cohort of setmelanotide Phase 3 trial in ac Jan 9, 2026 - $RYTM
Praxis tees up another approval filing; Geron turns to layoffs
“Collaborative discussions” with the FDA encouraged Praxis to submit early next year an approval filing for its epilepsy drug. Elsewhere, Rezolute shares plunged and Centessa announced a new CEO. Dec 12, 2025 - $RYTM
Is It Too Late to Invest in Rhythm Pharmaceuticals After Its 2025 Rally?
If you are wondering whether Rhythm Pharmaceuticals is still worth considering after its huge run, or if the best gains are already behind it, you are not alone. That is exactly what this article will explore. The stock has surged, with shares up 11.3% over the last week, 17.8% over the past month, and 95.8% year to date. That builds on a 111.2% 1-year return and more than a tripling over 3 and 5 years. Much of this momentum has been fueled by growing investor enthusiasm around Rhythm's... Dec 12, 2025 - $RYTM
Rhythm Pharmaceuticals (RYTM): Reassessing Valuation After Positive Prader-Willi Data and Phase 3 Trial Plans
The latest jump in Rhythm Pharmaceuticals (RYTM) shares is tied directly to encouraging preliminary Phase 2 data for setmelanotide in Prader Willi syndrome, where patients showed reductions in both BMI and hyperphagia. See our latest analysis for Rhythm Pharmaceuticals. That clinical update lands on top of powerful momentum in the stock, with a roughly 96% year to date share price return and a three year total shareholder return above 300%, signaling that investors are steadily repricing... Dec 12, 2025 - $RYTM
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple